Risk-based U.S. COVID-19 vaccine policy for 2026–2027

The FDA approved four updated 2026–2027 COVID-19 vaccine formulations targeting XFG, with narrower or risk-based indications by age and underlying condition. Independent effectiveness, safety, uptake, and access data remain limited; California's activity advisory underscores ongoing seasonal circulation, while viral and cancer-related claims in advocacy material are unsupported.